Imuran is a well-established immunosuppressant used to prevent organ transplant rejection and to treat autoimmune conditions such as rheumatoid arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), autoimmune hepatitis, and others. By dampening overactive immune responses, it can reduce inflammation and help maintain remission, but it also increases susceptibility to infections and requires regular blood monitoring. Typical care includes baseline genetic testing for TPMT/NUDT15 activity, periodic CBC and liver function tests, and careful review of drug interactions. Because Imuran is a potent therapy with boxed warnings, it should be used only under the guidance of a qualified clinician.
Imuran is an immunosuppressant that helps prevent the immune system from attacking transplanted organs and from driving autoimmune inflammation. In solid organ transplantation (kidney, liver, heart), azathioprine is used with other agents to prevent rejection. In autoimmune diseases, it is a steroid-sparing therapy that helps maintain remission and reduce flares in conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, autoimmune hepatitis, systemic lupus erythematosus, myasthenia gravis, and certain dermatologic disorders (e.g., pemphigus). Because its onset is gradual, patients often continue short-term steroids or other agents until azathioprine reaches full effect.
Dosing is individualized based on indication, body weight, genetics, and tolerance. Typical maintenance doses range from about 1 to 3 mg/kg/day orally, taken once daily or divided, with food to reduce GI upset. Transplant regimens may start higher and adjust over time; autoimmune indications often begin at the lower end and titrate upward. Onset of benefit usually takes 6 to 12 weeks, and full effect may take longer. Never change the dose without clinician guidance. Do not crush or split tablets unless a pharmacist confirms it is safe; handle broken tablets carefully and wash hands after handling.
Serious risks include bone marrow suppression (low white cells, platelets, anemia), hepatotoxicity, pancreatitis, increased infection risk, and potential malignancy (notably non-melanoma skin cancer and lymphomas). Before starting, clinicians commonly check thiopurine methyltransferase (TPMT) and NUDT15 activity, as reduced function dramatically increases risk for myelosuppression. Baseline and regular labs are essential: CBC and liver enzymes frequently during initiation (e.g., every 1–2 weeks initially), then spaced out (e.g., monthly to every 3 months) once stable. Report signs of infection, unusual bruising/bleeding, severe fatigue, dark urine, yellowing skin/eyes, or severe abdominal pain promptly.
Avoid live vaccines while immunosuppressed; discuss vaccination plans with your clinician before starting therapy. Use sun protection and schedule routine skin checks to reduce skin cancer risk. Alcohol should be limited to protect the liver. In pregnancy, azathioprine has been used when benefits outweigh risks, particularly in transplant and IBD settings; individual counseling with obstetrics and the prescribing specialist is advised. Breastfeeding may be compatible in some cases; discuss with your clinician. People with chronic infections, active malignancy, or significant liver disease require careful risk-benefit evaluation.
Imuran is contraindicated in patients with known hypersensitivity to azathioprine or 6-mercaptopurine. Severe deficiency of TPMT or NUDT15 is a major risk factor for life-threatening myelosuppression and generally warrants avoiding standard dosing; specialists may consider alternative therapies or very carefully adjusted regimens under intensive monitoring. Use is typically deferred in the setting of uncontrolled serious infection. Always review your full medical history and all medications with your prescriber before starting azathioprine.
Common reactions include nausea, loss of appetite, and mild abdominal discomfort, often improved by taking the dose with food. Headache, fatigue, or mild hair thinning can occur. More serious but less common effects include bone marrow suppression (manifesting as frequent infections, mouth sores, fever, easy bruising/bleeding), liver toxicity (jaundice, dark urine, right upper abdominal pain), pancreatitis (sudden severe abdominal pain with nausea/vomiting), and hypersensitivity reactions (fever, rash, muscle/joint pains). Long-term use is associated with increased risks of certain cancers, especially non-melanoma skin cancers and lymphomas; regular dermatologic checks and sun protection are important.
Seek urgent care for high fever, severe sore throat, unusual bleeding, yellowing of the eyes/skin, severe abdominal pain, chest tightness, or signs of anaphylaxis (facial swelling, wheezing, dizziness). Your clinician may adjust the dose or pause treatment based on lab results or symptoms. Never stop abruptly without medical advice, particularly in transplant patients where rejection risk is high.
Key interactions can significantly alter safety. Allopurinol and febuxostat increase levels of azathioprine’s active metabolites; co-use requires major dose reduction with allopurinol and is generally avoided with febuxostat. Aminosalicylates (mesalamine, sulfasalazine), trimethoprim-sulfamethoxazole, and ACE inhibitors may heighten myelosuppression risk. Warfarin effectiveness may be reduced. Ribavirin can increase toxicity. Live vaccines should be avoided; discuss inactivated/shingrix, influenza, and other vaccines with your clinician. Always provide a complete list of prescriptions, OTCs, supplements (e.g., echinacea, St. John’s wort), and recent antibiotics to your pharmacist and prescriber before starting or changing azathioprine.
If you miss a dose, take it when remembered unless it is close to the next dose. If it is near the next scheduled time, skip the missed dose and resume your regular schedule. Do not double up. If you frequently miss doses or have trouble tolerating the medication, contact your clinician to discuss solutions or alternative regimens.
Suspected overdose can cause severe nausea/vomiting, diarrhea, profound fatigue, infections, bleeding, or unusual bruising. Seek immediate emergency care and contact Poison Control at 1-800-222-1222 (U.S.). Bring the medication bottle and an updated medication list. Do not attempt to self-treat. Follow-up blood tests may be necessary to monitor marrow and liver function.
Store Imuran tablets at room temperature (generally 68–77°F or 20–25°C), away from moisture and direct light, in the original tightly closed container. Keep out of reach of children and pets. Because azathioprine is a cytotoxic medication, avoid crushing tablets; if a tablet breaks, avoid touching powder, wash hands after handling, and clean surfaces. Ask your pharmacy about safe disposal options—do not flush unless instructed.
In the United States, Imuran (azathioprine) is a prescription-only medication due to significant risks and the need for ongoing monitoring. It is not legal or safe to buy Imuran without a prescription. Reputable pharmacies dispense it only after a licensed clinician evaluates you and issues a valid prescription. Be cautious of websites offering azathioprine without medical review; they may be unsafe, counterfeit, or unlawful and can put your health at risk.
HealthSouth Rehabilitation Hospital of Manati supports a legal and structured care pathway: we work with valid prescriptions from your clinician and can help connect you with legitimate telehealth or local providers for appropriate evaluation, labs, and monitoring when needed. Our pharmacists review your medications for interactions, verify dosing, and provide counseling to promote safe, effective use—always within U.S. regulations and best-practice standards.
Imuran is the brand name for azathioprine, a thiopurine immunosuppressant that converts to 6-mercaptopurine and blocks purine synthesis, reducing the proliferation of T and B lymphocytes to calm overactive immune responses.
Doctors use azathioprine to treat inflammatory bowel disease such as Crohn’s disease and ulcerative colitis, rheumatoid arthritis, autoimmune hepatitis, certain dermatologic and renal autoimmune disorders, and to help prevent transplant rejection in select regimens.
Benefits are gradual; many patients notice improvement after 6 to 12 weeks, and the full effect may take 3 to 6 months, so it is often paired with faster-acting medicines early on.
Dosing is individualized and commonly weight based (often in the range of 1 to 3 mg per kg per day), adjusted for response, side effects, and metabolizer status under clinician supervision.
Before starting, clinicians often check TPMT and NUDT15 activity or genotype plus baseline blood counts and liver enzymes; during treatment, complete blood counts and liver tests are monitored frequently at first (for example every 1 to 2 weeks), then spaced out once stable.
Nausea, loss of appetite, fatigue, mild hair thinning, mouth sores, and increased susceptibility to infections are the most common, and taking the dose with food or splitting the dose sometimes helps nausea.
Call your clinician promptly for fever or chills, sore throat, unusual bruising or bleeding, severe abdominal pain (possible pancreatitis), yellowing of the skin or eyes, dark urine, severe rash, or shortness of breath.
Azathioprine slightly raises the long-term risk of lymphoma and non-melanoma skin cancer, especially with prolonged use or when combined with biologics; sun protection, skin checks, HPV screening, and regular labs help mitigate risk.
Light to moderate alcohol may be acceptable for some patients, but heavy drinking increases liver risk; ask your clinician what is safe for you and avoid alcohol if your liver tests are abnormal.
Inactivated vaccines (influenza, COVID-19, pneumococcal, hepatitis B) are recommended; live vaccines should generally be avoided during immunosuppression and given before starting therapy when possible.
Many specialists continue azathioprine during pregnancy when benefits outweigh risks because fetal exposure is low; very small amounts enter breast milk, and some clinicians advise timing feeds 4 hours after dosing to minimize infant exposure—always coordinate with your obstetrician and pediatrician.
Major interactions include allopurinol and febuxostat (can dangerously raise azathioprine levels), warfarin (reduced effect), ACE inhibitors and trimethoprim-sulfamethoxazole (additive marrow suppression), and aminosalicylates (can increase thiopurine effect); never start or stop interacting drugs without medical guidance.
Take it when you remember if it is within a few hours, otherwise skip the missed dose and resume your usual schedule; do not double up.
Do not stop suddenly unless your clinician tells you to, because disease flares can occur; in serious infections or surgery, your care team may advise holding and then restarting.
You should see fewer symptoms and less need for steroids over time, with improved inflammatory markers and stable blood counts on monitoring.
People with a known azathioprine or 6-mercaptopurine allergy, a history of thiopurine-induced pancreatitis, severe TPMT or NUDT15 deficiency, or active serious infections typically should not take it; your clinician will assess your individual risks.
Take with food, consider split dosing, stay hydrated, use sun protection, keep vaccinations up to date, practice hand hygiene, and report early signs of infection or lab abnormalities.
Yes, FDA-approved generics are bioequivalent to brand Imuran, though sticking with one manufacturer can minimize minor variability; your pharmacist and clinician can help keep supplies consistent.
A common schedule is every 1 to 2 weeks for the first 1 to 2 months, then monthly for several months, and every 2 to 3 months once stable, or more often if doses change or labs fluctuate.
Azathioprine is a prodrug of 6-mercaptopurine (6-MP); both are thiopurines with similar efficacy and safety profiles, but dosing differs and some patients tolerate one better than the other.
They have comparable onset; both usually take 6 to 12 weeks to show benefit and several months for maximal effect.
Overall rates are similar, though some patients report less nausea on 6-MP; risks of myelosuppression, liver enzyme elevations, pancreatitis, infections, and malignancy are broadly comparable.
Both can cause liver test elevations; in some people who preferentially form 6-MMP metabolites, switching from azathioprine to 6-MP or using low-dose thiopurine plus allopurinol can reduce hepatotoxicity under specialist monitoring.
Clinicians often use an approximate azathioprine to 6-MP conversion of 2 to 1 by milligrams, then individualize based on weight, labs, and tolerability rather than relying on a fixed ratio.
Yes, both require TPMT and NUDT15 consideration and the same pattern of complete blood counts and liver enzyme tests during dose titration and maintenance.
They share key interactions, including with allopurinol and febuxostat, warfarin, ACE inhibitors, and trimethoprim-sulfamethoxazole; always coordinate changes with your prescriber.
Acute pancreatitis is an idiosyncratic class effect of thiopurines and occurs at similar low rates; if it happens on one thiopurine, the other is usually avoided.
Both thiopurines have similar safety profiles and are often continued during pregnancy and lactation when benefits outweigh risks, with shared monitoring and coordination with obstetric care.
Thioguanine is another thiopurine that can work when AZA or 6-MP are not tolerated, but it has a higher risk of serious liver injury such as nodular regenerative hyperplasia, so it is reserved for select cases under specialist care.
Thioguanine may relieve gastrointestinal intolerance in some, but its liver toxicity risk is higher than AZA or 6-MP, so the safety tradeoff must be weighed carefully.
For patients who shunt to hepatotoxic 6-MMP, clinicians sometimes add allopurinol and reduce the thiopurine dose to about 25 to 33 percent to optimize therapeutic metabolites; this strategy can improve efficacy and tolerability but requires expert oversight and close labs.
Both are inexpensive generics in many regions; availability and copays can vary by pharmacy and insurer, so checking both options can be worthwhile.
Guidelines view AZA and 6-MP as largely interchangeable for maintenance of remission; choice depends on prior response, side effects, metabolite patterns, and patient preference.
Historically azathioprine has been used more in transplant regimens, though many centers now favor mycophenolate; when a thiopurine is selected, azathioprine is more commonly chosen than 6-MP.
Skin cancer risk is a class effect, so the same precautions apply to AZA, 6-MP, and thioguanine: limit UV exposure, use broad-spectrum sunscreen, wear protective clothing, and schedule regular skin exams.